Find Clinical Trials

October 9, 2024 in Gastrointestinal (GI)

S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) (NCT 06203600)

Read More
July 30, 2024 in Gastrointestinal (GI)

EA2212

A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Read More
May 29, 2024 in Gastrointestinal (GI)

A022106

Phase II/III second-line NABPLAGEM vs. nab-paclitaxel/gemcitabine in BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM)
Read More
April 22, 2024 in Gastrointestinal (GI)

EAY191-A6

A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations
Read More
March 11, 2024 in Gastrointestinal (GI)

A022004

Randomized trial of consolidation targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer
Read More
January 8, 2024 in Gastrointestinal (GI)

M24-052/LIVIGNO-2

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who…
Read More
May 31, 2023 in Gastrointestinal (GI)

A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR)
Read More
April 24, 2023 in Gastrointestinal (GI)

A022102

A022102: A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Read More
March 8, 2023 in Gastrointestinal (GI)

A022104

The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients with Locally Advanced…
Read More
February 14, 2023 in Gastrointestinal (GI)

EA2192: APOLLO

A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Read More
October 14, 2022 in Gastrointestinal (GI)

SGNTUC-029

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with…
Read More
September 14, 2022 in Gastrointestinal (GI)

GI003

GI003: A Phase III Randomized Trial of Protons Versus Photons For Hepatocellular Carcinoma
Read More
August 31, 2022 in Gastrointestinal (GI)

C-14 (CORRECT-MRD II)

CORRECT-MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease
Read More
July 11, 2022 in Gastrointestinal (GI)

WF1806

WF-1806: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M and M Study (NCT03998202)
Read More
July 11, 2022 in Gastrointestinal (GI)

S2001

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
Read More
July 11, 2022 in Gastrointestinal (GI)

S1922

S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

GI008

GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NCT 05174169)
Read More
June 30, 2022 in Gastrointestinal (GI)

GI006

GI006: Phase III Randomized Trial of Proton Beam Therapy (PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Read More
June 30, 2022 in Gastrointestinal (GI)

GI005

GI005: Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA)
Read More
June 30, 2022 in Gastrointestinal (GI)

GI004

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch…
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2201 – suspended 5/9/23

EA2201: A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2187

*Study Suspended 3/31/21.  EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2186

EA2186, A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) (NCT)
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2183

EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma
Read More